A5031662825- Glioma Diagnosis and Treatment
- Immune cells in cancer
- Nanoparticle-Based Drug Delivery
- Nanoplatforms for cancer theranostics
- Endoplasmic Reticulum Stress and Disease
- interferon and immune responses
- Circular RNAs in diseases
- Inflammasome and immune disorders
- Histone Deacetylase Inhibitors Research
- Cancer-related molecular mechanisms research
- Intracranial Aneurysms: Treatment and Complications
- RNA Interference and Gene Delivery
- Dendrimers and Hyperbranched Polymers
- Cancer therapeutics and mechanisms
- MicroRNA in disease regulation
- Biopolymer Synthesis and Applications
- Cerebrovascular and Carotid Artery Diseases
- Transgenic Plants and Applications
- Oropharyngeal Anatomy and Pathologies
- Cancer-related Molecular Pathways
- Skin and Cellular Biology Research
- Microtubule and mitosis dynamics
- Cancer Research and Treatments
Hebei Medical University
2025
Affiliated Hospital of Hebei University
2025
Nanjing Medical University
2020-2025
Jiangsu Province Hospital
2025
Central Hospital of Zibo
2024
Nanjing Brain Hospital
2022
Kaohsiung Medical University
2011
Abstract Tumor recurrence remains the major cause of management failure after surgical resection glioblastoma (GBM). Immunotherapy has potential to effectively eradicate tumors and trigger immune memory prevent tumor but not improve outcomes GBM patients. Here, an injectable, reactive oxygen species‐degradable therapeutic hydrogel (ADU‐AAV‐PD1@Gel), capable sustained local release soluble PD‐1 (sPD‐1) stimulator interferon gene (STING) agonist ADU‐S100 (ADU), is developed applied in a model....
Introduction: Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest increases sensitivity of glioma TMZ. Therefore, limit TMZ in glioma, an angiopep-2 (A2)-modified polymeric micelle (A2PEC) embedded with a small interfering RNA (siRNA) targeting PLK1 (siPLK1) was developed (TMZ-A2PEC/siPLK). Materials Methods:...
Radiotherapy (RT) has been the standard-of-care treatment for patients with glioblastoma (GBM); however, clinical effectiveness is hindered by therapeutic resistance. Here, we demonstrated that tumor immune microenvironment (TIME) exhibited immunosuppressive properties and high expression of Golgi phosphoprotein 3 like (GOLPH3L) in RT-resistant GBM. Our study showed GOLPH3L interacted stimulator interferon genes (STING) at aspartic acid residue 184 after RT, leading to coat protein complex...
Carotid artery stenosis (CAS) often goes undetected until it reaches an advanced stage, which can result in serious complications. The present study evaluated the potential of long noncoding RNA (lncRNA) LINC01088 as a biomarker for CAS. 92 CAS patients and healthy controls (Control group) were included. RT-qPCR was performed to assess relative levels miR-195-5p. Receiver operating characteristic (ROC) curve used evaluate diagnostic LINC01088. relationship between miR-195-5p identified by...
Objective: This study aimed to evaluate the clinical outcomes of a combined surgical approach involving carotid endarterectomy (CEA) and artery stenting (CAS) for management patients with severe bilateral atherosclerotic stenosis. Methods: A retrospective analysis was conducted on data 19 diagnosed stenosis who were hospitalized between June 2019 January 2022. The efficacy CEA CAS analyzed. Results: Postoperative imaging confirmed complete resolution stenosis, restored lumen patency,...
Tumor-associated macrophages (TAMs) are highly plastic tumor-infiltrating immune cells. Their reprogramming has emerged as a pivotal strategy in antitumor immunotherapy. The TLR7/8 agonist, IMDQ, significant potential for but lacks target specificity. To address this challenge, we developed novel folate receptor beta (FR-β) targeting chimeric molecules using 6-substituted pyrrolo[2,3-d]pyrimidines high-affinity ligands, which demonstrate superior FR-β capability compared with classical folic...
Glioblastoma (GBM) is one of the most lethal forms human cancer, with very few long-term survivors. In addition to surgery, chemotherapy still an important strategy. Unfortunately, GBM faces two main challenges: first, in GBM, epidermal growth factor receptor (EGFR) overexpression results chemoresistance; second, temozolomide (TMZ) lacks target specificity, which can lead a reduction concentration and side effects GBM. Nowadays, development nanomedicine systems for applications tumor...
Folic acid (FA) was selected to link with macromolecules for the selective and specific delivery of doxorubicin (DOX) folate receptor (FR)-positive tumor cells, because high binding affinity FA tumor-associated FR. We synthesized folate-mediated chondroitin sulfate (FA-PEG-ChS) cell targeting non-folate-mediated naproxen-linked (Nap-PEG-ChS) comparison. Both aforementioned polymers contain a PEG1000 spacer. encapsulated an anticancer agent, DOX, during formation complexes chitosan....
Glioma, a prevalent primary tumor of the central nervous system, is targeted by molecular therapies aiming to intervene in specific genes and signaling pathways inhibit growth spread. Our previous bioinformatics study revealed that significant CDC6 overexpression gliomas was closely correlated with poor patient prognosis. Through qPCR, western blotting, immunohistochemistry, we will further validate expression clinical glioma specimens, while effects silencing overexpressing U87 LN229 cell...
Tumor recurrence is an important factor indicative of a poor prognosis in glioblastoma (GBM). Many studies are attempting to identify effective therapeutic strategies prevent the GBM after surgery. Bioresponsive hydrogels capable sustaining locally released drugs frequently used for local treatment However, research limited due lack suitable relapse post-resection model. Here, model was developed and applied hydrogel investigations. This constructed based on orthotopic intracranial model,...
Flexible Optoelectronics In article number 2205038, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen, and co-workers present an injectable, reactive oxygen species-responsive therapeutic hydrogel (ADU-AAV-PD1@Gel), capable of sustained local release soluble PD-1 (sPD-1) STING agonist ADU-S100. The ADU-AAV-PD1@Gel combined with radiotherapy generates a robust antitumor immune response induces long-term memory to prevent glioblastoma recurrence.